Current Sackler Family Net Worth and Holdings
The Sackler family remains one of the wealthiest dynasties in the United States, with estimated combined assets still in the tens of billions of dollars despite massive legal settlements. The family's wealth originated from Purdue Pharma, the maker of OxyContin, and from investments in art, real estate, and financial markets. While Purdue Pharma filed for bankruptcy in 2019, the family retained significant personal wealth through trusts, holding companies, and diversified portfolios. Forbes and other financial outlets continue to track Sackler-linked entities and estimate their collective net worth based on public filings and asset disclosures.
Several Sackler family members remain on global billionaire and multimillionaire lists, with individual fortunes tied to stakes in companies outside Purdue. The family's investment arm, Thoma Bravo, and other private equity vehicles have generated returns independent of the opioid crisis. Real estate holdings in New York, London, and other major cities form a visible part of the Sackler portfolio. The exact distribution of wealth among family members is difficult to pin down because much of it sits in opaque trusts and offshore structures, but available data suggests the family's overall financial position remains robust.
Purdue Pharma Bankruptcy and Settlement Impact
Purdue Pharma's 2019 bankruptcy filing was designed to shield the Sacklers from personal liability while creating a settlement fund for opioid crisis victims. The company emerged from bankruptcy in 2023 under new ownership, with the Sacklers contributing billions to the settlement trust. However, the Sacklers themselves were not required to surrender personal assets, and the bankruptcy plan specifically protected family members from future civil claims related to Purdue's conduct. The settlement structure has been criticized by victims' advocates and legal experts as allowing the family to retain wealth while shifting corporate liabilities to a bankruptcy trust.
The Sackler family's role in Purdue Pharma's marketing of OxyContin has been documented extensively in congressional hearings, lawsuits, and investigative journalism. Internal documents revealed that the company knew about addiction risks yet pushed aggressive sales strategies. The family's involvement in these decisions, combined with their use of bankruptcy protections, has fueled public debate about whether the Sacklers truly lost significant wealth. While Purdue's bankruptcy reduced the company's value, the Sacklers' personal fortune appears largely intact, with ongoing income from diversified investments and asset sales.
Ongoing Legal and Financial Developments
Legal actions against the Sackler family continue in multiple jurisdictions, with some states and Native American tribes pursuing additional claims outside the Purdue bankruptcy settlement. The U.S. Supreme Court ruled in 2021 that certain bankruptcy releases for the Sacklers could proceed, but litigation persists in other courts. The family's legal strategy has focused on using bankruptcy protections to limit exposure while maintaining control over remaining assets and business interests. New York Attorney General Letitia James has pursued separate investigations into Sackler finances, and some of those cases remain active as of 2025.
Beyond Purdue, the Sackler family maintains connections to major art institutions and cultural organizations, with donations and naming rights tied to their wealth. The family's art collection, including works by major modern artists, represents a significant portion of their liquid and illiquid assets. Some Sackler-linked entities continue to invest in private equity, venture capital, and real estate through vehicles that are not directly tied to Purdue. Public records and financial disclosures offer partial visibility into these holdings, but the full scope of Sackler wealth remains difficult to quantify precisely, especially given the use of trusts and offshore structures that limit public transparency.